FDA provides new details on Diversity Action Plans for Clinical Trials. Check out this newsletter for quick insights!
The FDA now requires 𝗗𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗔𝗰𝘁𝗶𝗼𝗻 𝗣𝗹𝗮𝗻𝘀 for certain clinical studies. This ensures trials reflect real-world populations, leading to better outcomes for everyone. 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗳𝗼𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 & see how Maxis can help! 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: • Plans must set enrollment goals based on factors like age, race, and ethnicity. • These goals need a clear rationale and achievable strategy. #DiversityInClinicalTrials #ClinicalStudies #FDA #MaxisClinicalSciences 𝗦𝗼𝘂𝗿𝗰𝗲: FDA - https://lnkd.in/eT5AhNTP